Although the median eGFR in both groups in this study was in the seventies range, it has recently been reported that SGLT2 inhibitor therapy reduces uric acid levels in Grade 3 and Grade 4 CKD patients [33, 34]. This evidence concerns the gene SLC5A2 and chronic kidney disease.